

Patient Power Unleashed

May 23, 2019

Deanna Darlington

Advocacy Relations Director

Amgen



School of Medicine
& Health Sciences

THE GEORGE WASHINGTON UNIVERSITY

Amgen's History with AAKP

The Amgen Story Unlocking the Potential of Biology for Patients

1983

Led by CFO Gordon Binder, Amgen's Initial Public Offering on June 17, 1983, raises nearly \$40 million. The Company officially changes its name to Amgen.



At the time, Amgen was investigating a gene on a single fragment of DNA among 1.5 million fragments of the human genome.

After working tirelessly for two years, Amgen is successful. This groundbreaking achievement enables the creation of one of the most successful drugs in biotech history, EPOGEN® (epoetin alfa).

1989

On June 1, 1989, the FDA approves EPOGEN® (epoetin alfa). EPOGEN® is named Product of the Year by Fortune magazine.



2001

Amgen researchers add two sugar chains to erythropoietin, causing the protein to remain in the body longer. From this discovery, Aranesp® (darbepoetin alfa) is created.

2004

On March 8, 2004, Sensipar® (cinacalcet) is approved by the FDA.



School of Medicine
& Health Sciences
THE GEORGE WASHINGTON UNIVERSITY

ADVOCACY RELATIONS

OUR VISION

Together we make a valued difference in the lives of patients we serve.

OUR MISSION

To improve patient's lives and access to treatment through strong, mutually beneficial relationships with key patient, professional, and multi-stakeholder organizations, delivering on Amgen's mission to serve patients.

OUR STRATEGIC FOCUS AREAS

Partnering with Patient, Professional, and Multi-stakeholder Organizations in order to...



Elevate Disease Advocacy

Partnering to raise awareness and prioritize the disease within the market



Support Access to Treatment

Collaborating to support treatment equality, physicians' choice, optimal patient experience and reimbursement



Mobilize Advocacy for Healthcare Change

Working together to drive paradigm shifts in policy, regulatory, and other prevalent concerns across today's healthcare ecosystem



Optimize Advocacy Relations Function Across Amgen

Embedding the value of advocacy across development and commercialization, harnessing insights, creating synergies, and continuously improving

Patient Partnerships

Elevate
Disease
Advocacy



Optimize
Advocacy Relations
Function Across
Amgen



Amgen Patient Centricity

Patient Focused Innovation
Improving Serious Disease & Outcomes
Reaching More Patients
Access without Hurdles
Multi Stakeholder Relationships



School of Medicine
& Health Sciences
THE GEORGE WASHINGTON UNIVERSITY

Amgen's Foundational Programming



Support Access
to Treatment



Mobilize
Advocacy for
Healthcare Change



School of Medicine
& Health Sciences

THE GEORGE WASHINGTON UNIVERSITY

Amgen & AAKP – Enduring Relationship

- ▶ Amgen's mission is to serve patients
 - ▶ Amgen has commercialized more therapies in chronic kidney disease (CKD) than any other manufacturer
- ▶ Multiple decades of Amgen / AAKP partnership critical to this mission
 - ▶ Collaboration on patient education materials
 - ▶ Funding support for programs and meetings
 - ▶ Routine information sharing and ideation exchange
 - ▶ Clinical, policy and education



School of Medicine
& Health Sciences
THE GEORGE WASHINGTON UNIVERSITY

Backup Slide



School of Medicine
& Health Sciences

THE GEORGE WASHINGTON UNIVERSITY

Patient Engagement



Working Together for Patients

Patients, Physicians, Manufacturers, Payers, Policymakers,
Elected Officials, Caregivers

Why we work together?

Better Patient Care, Access to therapy, Innovative Treatments,
Disease Awareness